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Acquired von Willebrand syndrome (AvWS) is an uncommon complication of multiple myeloma (MM), and it
is believed to be connected with paraprotein. The aim of this study was to determine the incidence of AvWS
in patients with MM, and estimate the role of paraprotein in its occurrence. The study included 40 patients
with MM. The plasma level of paraprotein, platelet adhesion on glass pearls, plasma von Willebrand factor
antigen concentration, and ristocetin-induced platelet aggregation (RIPA) were measured initially. Absence
of RIPA was found in six patients with MM (15%); however, all six of them had normal levels of von
Willebrand factor antigen. Paraprotein was isolated from the serum of these patients. Platelet aggregation
was measured in six healthy donors before and after addition of the isolated paraprotein. RIPA was
significantly decreased in healthy donors in the presence of paraprotein (P,0.001). The same test was
repeated with added human immunoglobulins for intravenous use without any change in RIPA. A significant
negative correlation between plasma paraprotein level and RIPA was found (P,0.001). These
investigations have shown that paraprotein is associated with AvWS in patients with MM.
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Introduction
Von Willebrand factor (vWF) is a high molecular
weight glycoprotein (GP) that plays an important
role in hemostasis by reacting with platelet membrane
receptors.1 It is synthesized in endothelial cells and
megakaryocytes.2 At the site of vascular injury,
binding of vWF to subendothelial collagen induces
conformational changes in the vWF molecule that
lead to platelet activation through GP Ib and GP IIb/
IIIa, the principal platelet vWF receptors.2–4
Qualitative or quantitative abnormalities of vWF
result in von Willebrand disease (vWD), the most
common inherited bleeding disorder transmitted as
an autosomal, most frequently dominant trait, with
prevalence of 1–2% in the general population.5 There
are three main subtypes of vWD: (i) type 1 vWD is
partial deficiency of qualitatively normal vWF; (ii)
type 2 vWD is caused by functionally abnormal
vWF; and (iii) type 3 vWD represents a virtual
absence of vWF protein.2,5,6 Concerning laboratory
evaluation of vWD, due to assay limitations and
vWD heterogeneity, no single laboratory procedure
can detect all forms of vWD. However, various
panels are used in different laboratories, depending
on preference and availability. The classical test panels
for laboratory evaluation of vWD are: plasma level
of vWF antigen (vWF:Ag), vWF:ristocetin cofactor
activity, factor VIII:coagulant activity, vWF:collagen-
binding activity, ristocetin-induced platelet aggregation
(RIPA), vWF:multimers, and vWF:factor VIII binding
assay.7
In contrast to congenital disease, acquired von
Willebrand syndrome (AvWS) is a rare disorder,
most commonly associated with various underlying
diseases, with an estimated prevalence ranging
from 0.04 to 0.13% in the general population.3,8
The pathophysiology of AvWS is not completely
understood.8 Several pathogenic mechanisms have
been proposed: (i) specific inhibitory antibodies to
vWF; (ii) non-neutralizing autoantibodies to vWF
(immune complex); (iii) adsorption of vWF by
malignant cells; (iv) increased vWF proteolytic
degradation; and (v) decreased vWF synthesis.3,8–15
Most patients with AvWS (47%) had an underly-
ing lymphoproliferative or plasma cell proliferative
disorder.3 Multiple myeloma (MM) is a malignant
plasma cell neoplasia characterized by the prolifera-
tion of a single clone of plasma cells derived from B
cells in the bone marrow.16 The plasma cell clone
produces a monoclonal (M) protein, known as the
M-component, or paraprotein.16 It is believed that
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AvWS in MM is connected with paraprotein.3,17
Proposed possible pathophysiologic mechanisms, in
rare published investigations, include an inhibiting
role of paraprotein by binding to vWF, or platelets
vWF receptors, and adsorption of vWF by myeloma
cells because they show aberrant expression of GP
Ib.3,8,12
The aim of this study was to estimate the incidence
of AvWS in patients with MM and the role of
paraprotein in its origin.
Materials and Methods
This research included 40 patients with MM, among
whom 29 were newly diagnosed and were in relapse.
The characteristics of the patients are shown in
Table 1. All patients were evaluated before treatment,
and they received no antiaggregant or anticoagulant
therapy. Only patients with a normal platelet count
(.1506109/l) were included. The following tests were
initially performed in all of them: bleeding time (BT),
prothrombin time (PT), partial thromboplastin time
(PTT), platelet adhesion, plasma level of vWF:Ag, and
RIPA. The concentration and type of paraprotein
were determined according to the diagnostic criteria
for MM from Durie et al.18 Paraprotein was separated
from six patients who had complete absence of RIPA.
Isolated paraprotein was added in plasma from six
healthy donors and the RIPA test was repeated. In
order to exclude the possibility of non-specific binding
of paraproteins to platelet receptors in vitro, the
platelet aggregation test was repeated again after
adding immunoglobulins for intravenous (i.v.) use to
plasma from the same healthy donors.
Routine hemostatic tests, PT and PTT, were deter-
mined on the coagulometer (Automated Coagulation
Laboratory). The control values for PT were 75–120%
(expressed as a percentage of the value for normal
plasma). For PTT, the values were 25–35 seconds. BT
was measured according to the Duke method and the
normal values were 60–180 seconds.
Plasma level of vWF:Ag was determined with an
enzyme-linked immunosorbent assay and the normal
range was 50–150%.
Platelet adhesion was measured by platelet reten-
tion on glass pearls by Salzman’s method.19 Blood
was taken directly from a vein (N) into a test tube,
while from another vein, blood was taken through a
system filled with glass pearls (n). Platelet adhesion
was determined according to the following formula:
[(N2n)/N]6100 and expressed as a percentage of
adhered platelets. Normal values are 20–60%.
Platelet aggregation was measured by Born’s
optical method.20 A sample of venous blood was
taken into a test tube containing anticoagulant
sodium citrate in the ratio 1 : 9. Plasma rich in
platelets was obtained by centrifugation at 800 rota-
tions/minute for 15 minutes. RIPA was determined
by adding 50 ml of ristocetin in concentration 1.2 mg/
ml in 450 ml of plasma rich in platelets. Aggregation
was recorded as the increase in light transmis-
sion through the mixture. The maximum aggregation
achieved, expressed as transmission unit percentage,
was determined from the aggregation curve graphic
record. Normal values of aggregation are 60–100%
(0.6–1.0).
The concentration and type of paraproteins were
determined by horizontal electrophoresis in 1% agar
gel at the electric field strength of 8 mA.
Paraproteins were partially fractionated from
serum by adding Rivanol solution (1.5%) to the
serum in the volume ratio 1 : 1. The mixture was left
overnight at 4uC, and then centrifuged for 10 minutes
at 3000 rotations/minute. The supernatant contains
IgG (so-called Rivanol-soluble IgG). The protein
concentration in the samples of isolated IgG was
determined by the tannin turbidimetric method. The
relative abundance of protein fractions was obtained
by densitometry of electrophoretically separated
fractions, using ImageQuant software (Molecular
Dynamics, San Diego, CA, USA). Horizontal elec-
trophoresis of IgG was performed in 1% agar gel at
the field strength of 8 mA per sample for 30–
40 minutes. Protein fractions were visualized by
staining with amido-black. The subclass of isolated
IgG paraproteins was determined by western blot
method. After electrophoretic separation of IgG on
agar gel, the proteins were transferred to a nitrocel-
lulose membrane and allowed to dry in the air. All
membranes were incubated with mouse monoclonal
antibodies specific for gamma1, gamma2, gamma3,
and gamma4 heavy chains of human IgG. Reaction
was visualized with a secondary antibody (goat
antibody to mouse IgG labeled with peroxidase)
and chloronaphthol as the substrate for peroxidase,
which, in the presence of H2O2, gives a blue–purple
precipitate.21–23
The interferential statistical procedures used here
are methods for estimating the significance of
differences: Student’s t-test for independent samples,
chi-square test, Fisher’s exact significance test, and
correlation methods (Pearson’s coefficient of linear
Table 1 Patients characteristics
Patient characteristics No. of patients %
Total 40
Diagnosis
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correlation and Spearman’s coefficient of range
correlation). Statistical significance was set at
P(0.05.
Results
Among our 40 patients with MM, RIPA was absent
in six of them (15%); more exactly, their level of
RIPA was 0%. Four patients were female and two
were male. The plasma level of vWF:Ag was in the
normal range in all of them. Decreased platelet
adhesion was found in two patients with absent
RIPA, disturbed PT in one of them, while BT and
PTT were in the normal range in all of them. Two
patients with AvWS had an evident bleeding syn-
drome, one with massive skin hematomas and the
other with prolonged epistaxis. Laboratory findings
for the six patients with AvWS are summarized in
Table 2.
Paraprotein of the IgG class was detected in 34
(85%) and IgA in six (15%) patients enrolled in this
study. All six patients with AvWS had IgG class
paraprotein, three with the lambda subclass and three
with the kappa subclass. Serum paraprotein concen-
trations were negatively correlated with RIPA
(P,0.001, rho520.671).
RIPA was measured in six healthy donors before
and after addition of paraprotein isolated from the
serum of patients with absent RIPA, in vitro. The
change in the average value of the maximal level of
RIPA before and after adding paraproteins to plasma
from healthy donors was statistically significant
(t58.032, df55, P,0.001; Fig. 1). In contrast to
these results, after the addition of immunoglobulins
for i.v. use to plasma of the same healthy donors,
there was no significant change in RIPA (Fig. 2).
Three patients achieved complete remission of
MM, i.e. after disappearance of paraprotein from
their serum, repeated RIPA tests were normalized.
Discussion
AvWS is reported in association with monoclonal
gammaglobulins, lymphoproliferative disorders such
as lymphomas, myelomas, and Wilms’ tumors, and
autoimmune disorders, suggesting deficiency of an
immunological etiology.4 Laboratory findings con-
cerning AvWS coexisting with these diseases are
similar to those for inherited type 2A vWD.17 The
monoclonal protein, paraprotein, in some patients
appeared to have specificity against vWF.3 Para-
protein inhibited the function of vWF by binding to
the vWF A1 domain, which is the GP Ib binding
domain.17 Moreover, Shiganawa et al. showed that
paraprotein inhibited RIPA by interference with the
A1 domain of vWF and directly bound the 39/34-kD
fragment of vWF that encompasses this domain.24
Impaired platelet function due to abnormal platelet
aggregation has been associated with non-specific
coating of platelet receptors by paraprotein.17 Para-
protein can also inhibit platelet function by speci-
fic binding to the vWF platelet receptor GP Ib,
thereby inhibiting binding of vWF to ristocetin-
stimulated platelets, and by binding to platelet IIb/
IIIa receptors.17,25,26
Among our 40 patients with MM, six (15%)
exhibited absence of RIPA but had normal plasma
levels of vWF:Ag and normal BT and PTT. Most of
them also had normal PT (five of six), but two sub-
jects showed decreased platelet adhesion. In accor-
dance with these data, our patients also had type 2
AvWS, i.e. a qualitative dysfunction of vWF. A
normal plasma level of vWF:Ag is specific for type 2
vWD, the most common type of AvWS in plasma cell
dyscrasias.7,17 BT, PT, and PTT are not specific tests















1 0 84 37 105 81 31.8
2 0 112 36 75 71 29.9
3 0 70 60 150 53 32.3
4 0 84 40 75 96 25
5 0 70 7.5 105 106 31.6
6 0 84 5 165 70 35
Figure 1 RIPA was significantly decreased after adding
paraproteins to plasma from healthy donors (P,0.001).
Figure 2 RIPA was not significantly changed after adding
immunoglobulins for intravenous use to plasma of healthy
donors.
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for vWD, and they are probably better used as a
more global screening assay for potential hypocoa-
gulopathies that might include vWD.7 Inhibitors of
vWF have been identified most frequently by inhibi-
tion of RIPA.27 The antibiotic ristocetin facilitates
GPIb-mediated platelet binding of vWF and provides
a functional assessment of vWF. In two patients
with AvWS, platelet adhesion was decreased, which
showed that vWF is dysfunctional.
The actual incidence of AvWS in MM has not been
precisely estimated. In the study of Mohri et al.,4
AvWS was diagnosed in three out of 42 patients with
MM, while an inhibitor to vWF was identified in
eight patients out of 25 with AvWS.4
In our investigation, paraprotein inhibited vWF in
six patients. All paraprotein were IgG class, three
IgGlambda subclass and three IgGkappa subclass.
Most inhibitors described earlier belonged to the
IgGkappa subclass of paraproteins.8 We showed that
paraprotein inhibited vWF leading to the type 2A
AvWS in patients with MM. Thus, paraprotein from
serum of these six patients with absence of RIPA
significantly decreased RIPA in plasma from six
healthy donors, in vitro. Addition of immunoglobu-
lins for i.v. use to healthy plasma nullified the effect
and so the possibility that paraprotein bound non-
specifically to platelet receptors was excluded. These
findings were supported by repeating RIPA in three
patients who had achieved complete remission of
MM, i.e. when paraprotein was not detectable in
their serum after a treatment, RIPA was normalized
in all three patients. Another finding in our study
supporting the importance of paraprotein in the
origin of AvWS was the significant negative correla-
tion between serum paraprotein level and RIPA.
Conclusion
This investigation showed that in patients with MM,
paraprotein caused AvWS, type 2A, either by binding to
vWF or by specific binding to vWF platelet receptors.
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